9091ÃÀ¸ß÷

English

¹ú²ú¿¹XaÖÊÁ¿ÈôºÎ£¿¶àÖÐÐÄÁÙ´²×êÑÐÀ´Í¨ÖªÄ㣡

°ä²¼ÓÚ£º2022-11-24

ÎÄÕÂÆðÔ´£º[ÖÐÎÄ]9091ÃÀ¸ß÷ÉúÎï


µ¼Ó

2022Äê11ÔÂ13ÈÕ£¬¡°´´Ö®Éù¡±µÚÆß½ìÖйú³¢ÊÔҽѧ´ó»á¡ª¡ª¡°ÑªË¨ÓëֹѪרÌâѧÊõÂÛ̳¡±ÔÚÏßÉÏ¡³Á½øÐС£»áÉϽøÐÐÁ˹ØÓÚ¿¹Xa¶àÖÐÐÄÁ˾ֵĻ㱨Óë·ÖÎö¡£ÄÇô¹ú²ú¿¹XaµÄÖÊÁ¿µ½µ×ÈôºÎÄØ£¿½ÓÏÂÀ´£¬Óױཫ´øÄúÈ«·½Î»ÏàʶһÏ¡£


ý½é£º

Ŀǰ£¬¾²ÂöѪ˨˨ÈûÐÔ¼²²¡£¨venous thromboembolism, VTE£©ºÍ¶¯ÂöѪ˨˨ÈûÐÔ¼²²¡³ÉΪµ¼ÖÂÈ«ÇòÈ˶¡éæÃüµÄµÚһλԭÒò¡£´óÎÞÊý¾²ÂöѪ˨ÓÉÓÚûÓÐÖ¢×´Ò×±»Â©Õï¡¢ÎóÕµ«VTEÊÇÄܹ»Ô¤·ÀµÄ£¬¿¹Äý¾ÍÊÇÔ¤·ÀºÍÒ½ÖεĻù´¡¡£µ«ÊÇÈôºÎÔ¤·À¿¹ÄýÒ½Öε¼ÖµijöѪÐÔ·çÏÕ£¬¡¶ÖйúѪ˨ÐÔ·ÀÖÎÖ¸ÄÏ¡·£¨2018£©¶ÔÓÚ·ÖÆç¿¹ÄýÒ©Îï¸ø³öÁËÓйصļà²âÖ¸±ê¡£

  • ÈôÀûÓÃUFHÒ½ÖΣ¬ÍƼö³ÖÐø¾²Âö¸øÒ©²¢Æ¾¾Ý»î»¯²¿ÃÅÄýѪøԭ¹¦·ò£¨APTT£©¼à²âÁ˾ֵ÷½Ú¼ÁÁ¿£¬Ö±ÖÁAPTTµ¢¸éÖÁ¿¹ÄýǰµÄ1.5~2.5±¶£¬»ò´ïµ½Ï൱ÓÚѪ½¬UFHˮƽ0.3~0.7 U/ml ʱµÄ¿¹ XaÒò×Ó£¨FXa£©»îÐÔˮƽ¡¾1C¡¿¡£

  • ÖðÈÕÐè´ó¼ÁÁ¿UFHÒ½ÖζøAPTT²»´ï±êʱ£¬ÍƼöͨ¹ý¼à²â¿¹FXaµÄˮƽÁìµ¼ÓÃÒ©¼ÁÁ¿¡¾1B¡¿¡£

  • ÀûÓÃLMWHÒ½Öμ±ÐÔDVTʱ£¬Èô¹é²¢ÑϳÁÉöÖ°Äܲ»È«£¨¼¡ôû¶Ï¸ùÂÊ<30 ml/minʱ£¬É÷ÓÃLMWH£©£¬½¨ÒéLMWH¼õÁ¿²¢¼à²â¿¹FXa»îÐÔ¡¾2C¡¿¡£



¡¶¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÒ½ÖÎÖйúר¼Ò¹²Ê¶£¨2015£©¡·¶ÔµÍ·Ö×Ó¸ÎËØµÄÒ½ÖÎÁìÓòÒ²¸ø³öÁ˽¨Ò飺»³Ì¥ÆÚ¼äÐ趨ÆÚ¼à²â¿¹Xa»îÐÔ£¬Æä·åÖµÓ¦ÔÚ×î½üÒ»´Î×¢Éäºó4h²â¶¨£¬¹ÈÖµÓ¦±ÉÈË´Î×¢Éäǰ²â¶¨£¬¿¹Xa»îÐÔÖ¸±êÁìÓòΪ0.6¡«1.0 IU£¯ml£¬Ã¿Ìì¸øÒ©1´ÎµÄÖ¸±êÁìÓòΪ1.0¡«2.0 IU£¯ml¡£

ºÜ¶à»ú¹¹Ê¹Óÿ¹XaÒò×Ó»îÐԲⶨ×÷Ϊ½ð³ß¶È²âÊÔ£¬ÒÔ¼à²âºÍµ÷ÕûÒ½ÖÎÐÔδ·Ö×é¸ÎËØºÍµÍ·Ö×Ó¸ÎËØÒ½ÖεÄÖÎÀí¡£

¡ª¡ª¡¶ELSO Anticoagulation Guideline¡·


ÏÔÉ«¿¹XaÒò×ӲⶨÊÇĿǰ¼à²âµÍ·Ö×Ó¸ÎËØºÍ»Ç´ï¸Î¿ûÄÆÒ½ÖεĽð³ß¶È¡£

¡ª¡ª¡¶Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux¡·



ʹÓÃUFHºÍLMWH½øÐп¹ÄýÒ½ÖÎʱ£¬ÏÂÁÐÈËȺ±ØÒª½øÐмà²â£º

#  Ó¤Ó×¶ùºÍ¶ùͯ

#  ÀÏÈË£¨´ºÇ85Ë꣩

#  Ìå³ÁÒì³£Õß

#  ¼¡ôû¶Ï¸ùÂÊÔÚ15¡«30 mL£¯minµÄÂýÐÔÉö²¡Õß

#  »³Ì¥¸¾Å®

#  ÓгöѪ·çÏյϼÕßµÈ

¿¹Xa»îÐÔ¼ì²â


¼ì²âµÀÀíΪ£ºÑù±¾ÖеĸÎËØÓ뿹ÄýѪø½áºÏÐγɸ´ºÏÎïºó£¬»áÓ벿ÃÅXa½áºÏ£¬²¢Ê¹ÕⲿÃÅXaʧ»î¡£Ôü×ÒµÄXa¿É½«ºÏ³ÉµÄÏÔÉ«µ×Îï·Ö»¯²úÉú¶ÔÏõ»ù±½°·£¨PNA£©£¬PNAÔÚ405nm´¦ÓÐ×î´óÎüÊշ壬ͨ¹ý²â¶¨¶ÔÏõ»ù±½°·µÄÐγÉÁ¿À´ÍÆËã¸ÎËØ»îÐÔ¡£


Öйú¡¤9091ÃÀ¸ß÷(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾

¿¹Xa»îÐÔ¼ì²âµÀÀíͼ



ÊÔ¼Á»úÄÜ


9091ÃÀ¸ß÷¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©Í¨¹ýÉ«²Ê±ä¶¯À´²â¶¨¿¹ÄýÇ¿¶È/ѪҩŨ¶È£¬ÏßÐÔ¿í£¬¿¹×ÌÈÅÄÜÁ¦Ç¿£¬¾«Ãܶȸߣ¬ÓëÊг¡Ö÷Á÷³§¼ÒÊÔ¼ÁÓйØÐÔÓÅÁ¼£¬R2£¾0.95£¬¿ÉÂú×ãÁÙ´²¼ì²âÐèÒª¡£


Öйú¡¤9091ÃÀ¸ß÷(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾

£¨Êý¾ÝÆðÔ´£º¿¹Xa¶àÖÐÐÄÒ½ÔºÑù±¾±È¶ÔÊý¾Ý£©


Ó׽᣺

¿¹Xa»îÐÔÊÔÑé¿ÉÓÃÓÚUFH¡¢LMWH¡¢»Ç´ï¸Î¹ïÄÆ¡¢Ö±½ÓFXaÒÖÔì¼ÁµÈ¶àÖÖÒ©ÎÄýÇ¿¶È/ѪҩŨ¶ÈµÄ²â¶¨¡£

4¼ÒÈý¼×Ò½Ôº¹²Í¬²Î¼ÓÁËÖйú×êÑÐÐÍҽԺѧ»áµÄ¡°¹ú²ú¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©¶àÖÐÐÄÏîÄ¿»úÄÜÆÀ¼Û¡±£¨ÏîÄ¿±àºÅ£ºY2021FH-XSYZX04£©¿ÎÌ⣬¾­¶àÖÐÐij¢ÊÔÁ˾ÖÂÛÖ¤£º

£¨1£©¹ú²ú¿¹XaºÍ¶ÔÕÕÊÔ¼ÁµÄ²âÖµµÄÓйØÐÔÓÅÁ¼£ºÎÞÂÛÊÇͨ³£¸ÎËØ»¹ÊǵͷÖ×Ó¸ÎËØ£¬²âÖµÓйØÐÔ¾ùÔÚR2£¾0.95£¬¿ÉÂú×ãÁÙ´²¼ì²âÐèÒª£»

£¨2£©¹ú²ú¿¹XaÊÔ¼ÁÄܹ»Âú×ãÁÙ´²Ô¤ÆÚÓô¦£º9091ÃÀ¸ß÷¿¹XaÊÔ¼ÁºÐͨ³£¸ÎËØÏßÖ°Äܹ»×öµ½4IU/mL£¬²»½öÄܹ»Âú×ã˵Ã÷ÊéËùÐû³ÆµÄ1.2IU/mL£¬Í¬Ê±Äܹ»Âú×ãÁÙ´²ÉϵÄһЩÒì³£ÌØÊâ¸ßÖµÑù±¾µÄ¼ì²âÐèÒª£»

£¨3£©¹ú²ú¿¹XaÊÔ¼Á»úÄÜÆÀ¼ÛÓÅÁ¼£¬ÎªÁÙ´²Ìṩ¹ú²ú´úÌæµÄÑ¡Ôñ£º»úÄÜÆÀ¼ÛÊý¾ÝÏÔʾ£¬9091ÃÀ¸ß÷¿¹XaÊÔ¼ÁºÐµÄ¸÷Ïî»úÄÜÓÈÆäÊÇÔÚ¿¹×ÌÈÅÄÜÁ¦·½Ã棬¶ÔÖ±½Óµ¨ºìËØºÍѪºìµ°°×µÄ¿¹×ÌÈÅÄÜÁ¦ÓÅÓÚÔ­×°ÅäÌ×ÊÔ¼Á¡£

¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©¶©»õÐÅÏ¢


Öйú¡¤9091ÃÀ¸ß÷(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾



Öйú¡¤9091ÃÀ¸ß÷(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾



Öйú¡¤9091ÃÀ¸ß÷(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾


×¢£º±¾ÊÔ¼ÁºÐºÏÓÃÓÚ¸÷ÀàÖ÷Á÷»úÐÍ£¬»¶Ó­¸÷Ò½ÁÆ»ú¹¹¼°¾­ÏúÉÌÕ÷ѯ£¬ÏêÇé¿ÉÁªÏµÓÊÏ䣺sales@mdcbj.com.

¡¶¿¹Xa¶àÖÐÐÄÁ˾ֻ㱨Óë·ÖÎö¡·

ÅÔ¹Ûͨ·


PC¶ËÊäÈëÏ·½Á´½Ó¼´¿ÉµÇ¼ÄýÑªÔÆ½²ÌÃÆ½Ì¨£¬ÅÔ¹ÛÊÓÆµ£º

https://vfs.xet.tech/s/2YYnDS

H5¶Ë¼ø±ðÏ·½¶þάÂ룬¼´¿ÉÌø×ªÖÁÊÓÆµÒ³Ã棺

Öйú¡¤9091ÃÀ¸ß÷(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾



²Î¿¼Îļþ

[1] ÖлªÒ½Ñ§»áÐÄѪ¹Ü²¡Ñ§·Ö»á·ÎѪ¹Ü²¡Ñ§×é.¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÒ½ÖÎÖйúר¼Ò¹²Ê¶(2015)[J].ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾,2016,44(3):197-211.

[2] ÀµÓîÒ¢,Àî¹ðɺ,ÍõÖ¾Ã÷,µÈ.¿¹Xa»îÐÔ¼ì²âÔÚ¿¹ÄýÒ©Îï¼à²âÖеÄÀûÓÃ[J].ÏóÕ÷ÃâÒß·ÖÎöÓëÁÙ´²,2020,27(8):1444-1449.

[3] Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl): e737S-e801S.

[4] ÕźèÑÞ,Èξ²,ÃŽ£Áú.¿¹ÄýÒ©ÎïµÄ³¢ÊÔÊÒ¼à²â[J].ÖйúÐÄѪ¹ÜÔÓÖ¾,2019,24(6):565-570.

[5] Vandiver J W , Vondracek T G . Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin[J]. Pharmacotherapy, 2012, 32(6):546-558.

[6] The Extracorporeal Life Support Organization (ELSO).ELSO Anticoagulation Guideline.2014, 1-17.

[7] Babin JL, Traylor KL, Witt DM. Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux. Semin Thromb Hemost. 2017 Apr;43(3):261-269.

[8] ëøæÂ,ÀîÓÂÄÐ,Â¥ËÉ.¿¹Xa»îÐÔÔÚͨ³£¸ÎËØ¿¹Äý¼à²âÖÐÀûÓõÄ×êÑнøÕ¹[J].ÖйúÌå±íÑ­»·ÔÓÖ¾,2018,16(4):248-251.

[9] Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol. 2013;992:265-72. 

¸ßµÍ»¬¶¯²é¿´ÆëÈ«²Î¿¼Îļþ


END

ÎÄÕÂÆðÔ´£º9091ÃÀ¸ß÷ÉúÎï  |  Ôð±à£ºEcho  |  У¶Ô£ºCassie¡¢Ó×Ñ©



 
¡¾ÍøÕ¾µØÍ¼¡¿